The human APOE genotype is linked to several adult-onset neurodegenerative disorders, as APOE4 is associated with greater age-related cognitive decline, poorer outcomes following brain trauma, and higher risk of developing Alzheimer’s disease (Liu et al., 2013; Mahley, 2016; Flowers and Rebeck, 2020) compared with APOE3. Therefore, identifying supplements that mitigate APOE4-associated behavioral deficits could provide a great benefit for delaying the onset of neurodegenerative disorders. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.